HALO—on BAX 2q12 call they said they expected a CRL soon…
Exactly right—that’s why I said “as expected” in the header of #msg-78090032.
It would appear that many HALO investors violated one of the fundamental tenets of biotech investing: learn what your company’s partner is saying about your company’s drugs and drug candidates.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”